We also compared measured CgA levels in samples from patients with three different disease entities (NETs, non-NET pancreatic tumors, and prostate cancer) to healthy individuals to determine whether serum CgA can be used to discriminate among these groups. This evidence concerns the gene CGA and prostate cancer.